EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Preclinical Milestones in MECP2 Gene Transfer for Treating Rett Syndrome

Indumathy Jagadeeswaran, Jiyoung Oh, Sarah E Sinnett

Developmental Neuroscience · 2024

DOI: 10.1159/000539267 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Developmental Neuroscience, 2024. Verfasst von Indumathy Jagadeeswaran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, The University of Texas Southwestern Medical Center (UTSWMC), Dallas, Texas, USA, indumathy2311@gmail.com. Hauptthemen laut MEDLINE: Rett Syndrome, Methyl-CpG-Binding Protein 2, Genetic Therapy, Gene Transfer Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Rett syndrome (RTT) is a neurodevelopmental disorder caused by mutations in the transcriptional regulator methyl-CpG-binding protein 2 (MeCP2). After gene transfer in mice, exogenous MeCP2 expression must be regulated to avoid dose-dependent toxicity. Summary: The preclinical gene therapy literature for treating RTT illustrates a duly diligent progression that begins with proof-of-concept studies and advances toward the development of safer, regulated MECP2 viral genome designs. This design progression was partly achieved through international collaborative studies. In 2023, clinicians administered investigational gene therapies for RTT to patients a decade after the first preclinical gene therapy publications for RTT (clinical trial numbers NCT05606614 and NCT05898620). As clinicians take on a more prominent role in MECP2 gene therapy research, preclinical researchers may continue to test more nuanced hypotheses regarding the safety, efficacy, and mechanism of MECP2 gene transfer. Key Message: This review summarizes the history of preclinical MECP2 gene transfer for treating RTT and acknowledges major contributions among colleagues in the field. The first clinical injections are a shared milestone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rett SyndromeMethyl-CpG-Binding Protein 2Genetic TherapyGene Transfer TechniquesAnimalsHumansMice

Stichwörter der Autor:innen

Adeno-associated viral vector serotype 9Gene therapyMiRNA-responsive auto-regulatory elementMiniMECP2Rett syndrome

Substanzen

Methyl-CpG-Binding Protein 2MECP2 protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, The University of Texas Southwestern Medical Center (UTSWMC), Dallas, Texas, USA, indumathy2311@gmail.com.
  • Department of Pediatrics, The University of Texas Southwestern Medical Center (UTSWMC), Dallas, Texas, USA.
  • Eugene McDermott Center for Human Growth and Development, The University of Texas Southwestern Medical Center (UTSWMC), Dallas, Texas, USA.
  • Peter O'Donnell Jr. Brain Institute, The University of Texas Southwestern Medical Center (UTSWMC), Dallas, Texas, USA.

Zitieren

APA

Jagadeeswaran, I., Oh, J., & Sinnett, S. E. (2024). Preclinical Milestones in MECP2 Gene Transfer for Treating Rett Syndrome. Developmental Neuroscience. https://doi.org/10.1159/000539267

Vancouver

Jagadeeswaran I, Oh J, Sinnett SE. Preclinical Milestones in MECP2 Gene Transfer for Treating Rett Syndrome. Developmental Neuroscience. 2024. doi:10.1159/000539267

BibTeX
@article{Jagadeeswaran2024,
  author = {Jagadeeswaran, Indumathy and Oh, Jiyoung and Sinnett, Sarah E},
  title = {Preclinical Milestones in MECP2 Gene Transfer for Treating Rett Syndrome},
  journal = {Developmental Neuroscience},
  year = {2024},
  doi = {10.1159/000539267}
}
Kostenlos starten →